KIR3DL1 and acute lymphoblastic leukemia: In children with acute lymphoblastic leukemia (ALL) undergoing myeloablative HSCT, donor KIR B haplotypes and the centromeric–telomeric (ct)-KIR score have been associated with a lower incidence of relapse and prolonged event-free survival, regardless of minimal residual disease status (1).